Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 15/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 12/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30896148 | 1.00 | HSD17B2 (0.53) | HSD17B2HSD17B1CDC7TLR8DHODH | |
| SCHEMBL24932959 | 0.86 | HSD17B1 (0.44) | HSD17B2HSD17B1 | |
| SCHEMBL24933186 | 0.86 | HSD17B1 (0.44) | HSD17B2HSD17B1BRD4 | |
| SCHEMBL24933359 | 0.86 | HSD17B2 (0.50) | HSD17B2HSD17B1CDC7 | |
| SCHEMBL24932950 | 0.85 | HSD17B2 (0.52) | HSD17B2HSD17B1CDC7BRD4 | |
| SCHEMBL24933185 | 0.83 | PARP1 (0.46) | HSD17B2HSD17B1 | |
| SCHEMBL24933348 | 0.82 | CDC7 (0.47) | HSD17B2HSD17B1CDC7 | |
| SCHEMBL24933175 | 0.80 | HSD17B1 (0.42) | HSD17B2HSD17B1 | |
| SCHEMBL24933312 | 0.79 | BTK (0.42) | HSD17B2HSD17B1CDC7 | |
| SCHEMBL24933605 | 0.79 | HSD17B2 (0.41) | HSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |